The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study

Core Viewpoint - The first patient has been treated in the REVISE dose-ranging study by GenSight Biologics in collaboration with the 15-20 National Hospital in Paris, focusing on innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1]. Company Summary - GenSight Biologics is a biopharma company that specializes in developing and commercializing gene therapies aimed at treating retinal neurodegenerative diseases and central nervous system disorders [1]. - The company is listed on Euronext under the ticker SIGHT and is eligible for PEA-PME [1]. Industry Summary - The REVISE study is an open-label, single center trial that aims to enroll patients to evaluate the efficacy of the gene therapy being developed [1].